SCHEMBL6183311

SCHEMBL6183311

Cc1c(O)c(O)cc2occ(-c3ccc(O)cc3)c(=O)c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.67
ALDH1A1 P00352 6/20 0.66
MEN1 O00255 6/20 0.66
KMT2A Q03164 6/20 0.66
MAPT P10636 6/20 0.66
HPGD P15428 6/20 0.66
SMN1; SMN2 Q16637 6/20 0.66
NPC1 O15118 5/20 0.66
RAB9A P51151 5/20 0.66
TP53 P04637 5/20 0.66
CYP3A4 P08684 5/20 0.66
ALOX15 P16050 4/20 0.66
CYP2C9 P11712 4/20 0.66
CYP2C19 P33261 4/20 0.66
ESR1 P03372 3/20 0.66
ESR2 Q92731 3/20 0.66
TDP1 Q9NUW8 3/20 0.66
CYP1A2 P05177 3/20 0.66
AKR1B10 O60218 3/20 0.66
LMNA P02545 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12678865 0.90 ALDH1A1 (0.68) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL18326518 0.89 EGFR (0.70) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL30525493 0.87 MAPT (0.75) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL13279932 0.87 MAPT (0.75) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL17718213 0.83 EGFR (0.63) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL14341461 0.82 MEN1 (0.56) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL10620481 0.82 SMN1; SMN2 (0.76) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL18326541 0.81 EGFR (0.60) EGFRALDH1A1MEN1KMT2AMAPT
SCHEMBL16431178 0.81 EGFR (0.67) EGFRALDH1A1MEN1KMT2AMAPT
Tectorigenin SCHEMBL29353966 0.80 EGFR (1.00) EGFRALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1448542-A4 6-HYDROXY ISOFLAVONES, DERIVATIVES AND MEDICAMENTS INVOLVING SAME NOVOGEN RES PTY LTD (AU) 2005-11-16 EP disclosed
US-20050049424-A1 6-Hydroxy isoflavones derivatives and medicaments involving same NOVOGEN RESEARCH PTY LIMITED (AU) 2005-03-03 US disclosed
EP-1448542-A1 6-HYDROXY ISOFLAVONES, DERIVATIVES AND MEDICAMENTS INVOLVING SAME Novogen Research Pty. Ltd. (AU) 2004-08-25 EP disclosed
WO-2003035635-A1 6-HYDROXY ISOFLAVONES, DERIVATIVES AND MEDICAMENTS INVOLVING SAME NOVOGEN RESEARCH PTY LIMITED (AU) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049424-A1 6-Hydroxy isoflavones derivatives and medicaments involving same CYP2A7, CYP3A7, CASP7 EGFR 824/4885ALDH1A1 2384/4885MEN1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.